The Asia-Pacific (APAC) region is witnessing a significant shift in biopharma innovation as China continues to make strides in the industry. According to Ian Haydock, Editor-In-Chief, Insights, Asia-Pacific at Citeline, China’s increasing role in global biopharma R&D may impact outsourcing and manufacturing strategies throughout the region. Haydock is set to deliver a keynote speech at CPHI Japan 2023, which takes place from April 19-21.
China’s recent setbacks in the US, some of which are attributed to inadequate clinical data from US populations, are causing a shift in focus towards Southeast Asia and Japan as larger priorities. Almost a quarter of global R&D in new drugs and vaccines (24%) now occurs in China, with the US accounting for 51%. Oncology remains the most dominant therapeutic category, followed by rare diseases and neurology.
As the landscape of global biopharma innovation shifts, new distribution and regional manufacturing hubs could emerge. Japan’s innovation space has remained strong, but with relatively static growth. Research-based multinationals continue to face concerns regarding drug pricing systems in the country.
Haydock notes that the APAC region is characterized by a more diverse group of innovators, resulting in a potentially more dynamic supply side with a larger number of supply partners. CPHI Japan is expected to attract 7,000 executives from 95 countries this year, signifying a return to pre-pandemic prominence.
Jenny Leung, Regional Manager, Informa Markets, highlights the strong interest from international audiences in partnering with Japan and the wider region. The competition for partners and supply chain resources is intensifying, with Japanese companies reporting increased interest from potential partners.
CPHI Japan 2023 will mark the event’s 20th anniversary and will feature special events, including an award ceremony celebrating companies integral to Japan’s pharma industry.